Research Article
Real-Life Effectiveness and Tolerability of Brivaracetam in Focal to Bilateral and Primary Generalized Tonic-Clonic Seizures
Table 2
Seizure frequency and response rates at follow-up.
| | Baseline () | 3 months () | 6 months () | 12 months () |
| | BRV dose, median (IQR) | 75 (50-100) | 100 (100-200) | 150 (100-200) | 150 (100-200) | | FBTCS/GTCS | | | | | | Monthly seizures, median (IQR) | 0.3 (0-1) | 0 (0-0.3) | 0 (0-0.9) | 0 (0-0.1) | | Seizure-free, (%) | 50 (40.7) | 67 (69.1) | 71 (68.3) | 69 (73.4) | | Response rate, (%) | — | 75 (77.3) | 78 (75) | 78 (83) | | All seizures | | | | | | Seizures/month, median (IQR) | 1 (0-4.3) | 0.3 (0-3.3) | 0.1 (0-2) | 0 (0-1.7) | | Seizure-free, (%) | 27 (22) | 43 (44.3) | 52 (50) | 49 (52.1) | | Response rate, (%) | — | 57 (58.8) | 68 (65.4) | 62 (66.0) |
|
|
BRV: brivaracetam; FBTCS/GTCS: focal to bilateral tonic-clonic seizures/generalized tonic-clonic seizures; IQR: interquartile range.
|
